| Title： | Expert consensus on the management of Pseudomonas aeruginosa lower respiratory tract infections |
| Edition： | Updated |
| Classification： | Experts consensus |
| Field： | Comprehensive guideline |
| Countries and regions： | China |
| Guidelines users： | Physicians, nurses, infection control personnel, clinical microbiology lab technicians, hospital administrators |
| Evidence classification method： | GRADE |
| Development unit： | Chinese Thoracic Society Pulmonary Infection assembly |
| Registration time: | 2021-02-01 |
| Registration number： | IPGRP-2021CN028 |
| Purpose of the guideline: | Pseudomonas aeruginosa (PA) is one of the most common non-fermentative bacterium in the clinical setting, which is widely distributed in nature and can grow as a normal flora in human skin and contaminated medical devices and even disinfectant solutions.PA is an important conditional pathogen of hospital-acquired infections and the multi-drug resistance (MDR) rate is high. The lower respiratory tract is the most common site of hospital-acquired infections, and if it is caused by MDR-PA, the morbidity and mortality rate is high and the treatment is difficult, so it is particularly important to standardize the diagnosis and treatment of PA lower respiratory tract infections. In recent years, progress has been made in the drug resistance epidemiology, detection technology, treatment options and prevention of PA lower respiratory tract infections, therefore, the Chinese Thoracic Society Pulmonary Infection assembly initiated and organized experts to update the Expert consensus on the management of Pseudomonas aeruginosa lower respiratory tract infections developed in 2014. |
Latest registration
